CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
侵袭性大 B 细胞淋巴瘤中 CAR-T 细胞治疗失败后双特异性 T 细胞衔接器的疗效
英文原题：Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma.
查看英文原题
Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
目前，对于CAR-T 细胞（CAR-T 细胞）治疗后复发或进展的大B细胞非霍奇金淋巴瘤，尚无公认的标准治疗。双特异性T细胞衔接器（BiTE）已成为复发/难治性（R/R）大B细胞淋巴瘤（LBCL）的有效治疗方法。本系统综述和荟萃分析旨在评价CAR-T 细胞治疗失败后使用BiTE治疗LBCL的全部证据。结果显示，所有BiTE合并总体缓解率为51%，合并完全缓解率为31%。无进展生存期和总生存期的合并率分别为31%和48%。合并非复发死亡率为4%，凸显BiTE在这一人群中的相对安全性。现有数据不足以对不同BiTE产品进行比较。因此，未来仍需开展前瞻性、直接头对头随机对照试验，才能得出确定性比较结论。
展开英文摘要原文
No recognized standard of care exists at the present time for treatment for large B-cell non-Hodgkin lymphoma that relapses or progresses after chimeric antigen receptor T-cell (CAR T-cell) therapy. Bispecific T-cell engagers (BiTEs) have emerged as an effective treatment for patients with relapsed or refractory (R/R) LBCL. The purpose of this systematic review and meta-analysis is to appraise the totality of evidence on the role of BiTEs as treatment for LBCL after CAR T-cell therapy failure.
Results showed that pooled overall response rate of all BiTEs is 51 %, and the pooled complete remission rate is 31 %. The pooled rates for progression-free and overall survival are 31 % and 48 %, respectively. The pooled non-relapse mortality rate is 4 %, emphasizing the relative safety of BiTEs in this population. Available data did not permit a comparative assessment across different BiTE products.
Therefore, future research, specifically prospective head-to-head randomized controlled trials, would be necessary to make definitive comparisons.
论文信息
- 作者
- Kharfan-Dabaja MA、Reljic T、Abdel-Razeq S、Sarhan Z、Mohty R、Keller K、Iqbal M、Chavez JC
- 单位
- Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy program, Mayo Clinic, Jacksonville, FL, USA. Electronic address: KharfanDabaja.Mohamed@mayo.edu.United States
- 文献类型
- 系统综述 · 荟萃分析
- 期刊
- Current research in translational medicine2026 Apr-Jun
- 原文标识
- PubMed 42184607 · DOI 10.1016/j.retram.2026.103590